ExpressionEdits
ExpressionEdits is a Cambridge, UK-based biotechnology company that uses an AI-driven "Genetic Syntax Engine" combined with proprietary intronization technology to redesign synthetic DNA for enhanced protein expression, serving pharmaceutical and biotechnology partners and advancing an internal pipeline of previously infeasible therapeutic proteins.
- Company typePrivate
- Founded2021
- HeadquartersCambridge, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What ExpressionEdits does
ExpressionEdits is a privately held UK biotechnology company founded in 2021 and headquartered in Cambridge, with a registered office in Altrincham. The company has built a computational and experimental platform — the "Genetic Syntax Engine" — that uses AI and deep biological insights to redesign synthetic DNA (transgenes) for enhanced protein expression across therapeutic modalities. Its core proprietary method, "intronization," enables the integration of very small introns (as small as 80 base pairs) into gene constructs to boost expression without exceeding vector size constraints, addressing a class of difficult-to-express therapeutic proteins that conventional codon optimization and strong viral promoters cannot solve.
The platform is built around a paired wet-lab and dry-lab organization: computational teams led by CTO Dr. Leopold Parts develop AI models for transgene prediction and optimization, while experimental teams across RNA technologies, protein technologies, vector technologies, and translational biology generate the proprietary datasets that train and validate those models. ExpressionEdits pursues a dual business model combining (a) a partnership-led GTM motion targeting pharmaceutical and biotechnology companies — exemplified by a February 2025 collaboration with Boehringer Ingelheim to develop enhanced gene therapies — with (b) an internal pipeline of recombinant protein therapeutics, initiated under CSO Dr. Amrik Basran (appointed March 2025). Revenue is derived from custom co-development agreements, research collaborations, and potential milestone payments and royalties.
The company has raised approximately $13M in seed funding (May 2024) from a syndicate led by Octopus Ventures and redalpine, with participation from Acequia Capital, Amino Collective, BlueYard Capital, Hawktail Management, and Wilbe. It has grown to a team of approximately 17 people, anchored scientifically by co-founder Prof. Allan Bradley (Royal Society Fellow, genome engineering pioneer and founder of Kymab, acquired by Sanofi) and operationally led by CEO Dr. Kärt Tomberg, COO Dr. Rebecca Godfrey (former AbbVie, Roche), and Chair Dr. Paul Bolno (CEO of Wave Life Sciences).
ExpressionEdits firmographics
Firmographics- Name
- ExpressionEdits
- Legal name
- ExpressionEdits Ltd
- Website
- https://expressionedits.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ExpressionEdits is a Cambridge, UK-based biotechnology company that uses an AI-driven "Genetic Syntax Engine" combined with proprietary intronization technology to redesign synthetic DNA for enhanced protein expression, serving pharmaceutical and biotechnology partners and advancing an internal pipeline of previously infeasible therapeutic proteins.
- Ownership category
- akta.pro rank
ExpressionEdits industry classification
Industry- Product category
- Computational Biology Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
- akta.pro secondary industries
- Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI)
Keywords
Where ExpressionEdits is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
ExpressionEdits business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Strategic Partnerships and Collaborations: ExpressionEdits generates revenue through strategic co-development partnerships with pharmaceutical and biotechnology companies. The company collaborates on developing enhanced gene therapies and therapeutic proteins using their proprietary Genetic Syntax Engine. Revenue is derived from partnership agreements, research collaborations, and potentially milestone payments and royalties from successful therapeutic development.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
ExpressionEdits product offering
Product offeringCore offering
ExpressionEdits develops an AI-driven computational platform called the Genetic Syntax Engine that predicts transgene performance and redesigns synthetic DNA sequences to enhance protein expression. Combined with its proprietary intronization technology—which integrates small introns (as small as 80 base pairs) into gene constructs—the company enables the production of therapeutic proteins previously considered infeasible and supports gene therapy optimization across therapeutic modalities.
Product overview
ExpressionEdits offers a unified platform combining the Genetic Syntax Engine (a computational AI-driven platform) with proprietary intronization technology to enhance protein expression. The Genetic Syntax Engine serves as the core computational platform that uses AI and deep biological insights to predict performance and redesign transgenes, while the intronization technology provides the biological mechanism (strategic intron integration) to achieve enhanced expression. Together, these enable the company to overcome production challenges in therapeutic protein manufacturing and gene therapy applications.
Differentiator
Problem solved
Functional benefit
Products and services
- Genetic Syntax Engine AI-driven computational platform that perfects genetic grammar by predicting transgene performance and redesigning genetic sequences to unlock protein expression across therapeutic modalities, including gene therapies and recombinant proteins. Targeted at pharmaceutical and biotechnology R&D teams.
- Intronization Technology Proprietary method for enhancing gene expression by integrating small introns (as small as 80 base pairs, versus a typical intron size of over 1,500 base pairs) into genetic constructs, enabling production of proteins previously beyond reach using conventional methods. Targeted at therapeutic protein and gene therapy developers.
Quantifiable outcome
- Expression of proteins previously beyond reach using conventional methods
- +1 more outcomes
Companies that use ExpressionEdits
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
ExpressionEdits technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature2 records
ExpressionEdits partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Boehringer IngelheimflagshipExpressionEdits collaborates with Boehringer Ingelheim to develop enhanced gene therapies using the Genetic Syntax Engine platform. The collaboration aims to boost gene therapy potency and precision without altering core designs through optimal site and intron integration in circular intron RNAs (in-cRNAs).
Scale indicators2 records
Recent moves5 records
Expansion highlights5 records
ExpressionEdits competitors and assessment
Company assessmentDirect peers
- Deep Genomics: AI-driven platform for RNA biology and oligonucleotide therapeutics discovery, including target identification and RNA-targeted drug design. Directly comparable as an AI platform company optimizing nucleic-acid-based therapeutics for pharma partners.
- Dyno Therapeutics: Applies AI/ML to AAV capsid engineering for gene therapy, optimizing delivery vehicles for partners including Novartis and Roche. Highly comparable as an AI platform serving gene therapy developers via pharma partnerships.
- Generate Biomedicines: Generative AI platform for novel protein therapeutics design. Comparable as an AI-first biotech building both a partnership platform and an internal protein therapeutics pipeline, similar in strategy to ExpressionEdits.
- Cradle Bio: Machine learning platform for protein engineering, enabling partners to design improved proteins faster. Directly comparable as an AI/ML protein optimization platform serving biotech and pharma customers.
- Asimov: Synthetic biology platform using AI and genetic engineering tools to design mammalian cell systems and genetic constructs for therapeutic protein and gene therapy production. Comparable as an AI-driven platform optimizing transgene and expression system design.
Emerging players
- Tessera Therapeutics: Gene writing technology platform that designs and writes therapeutic genetic sequences. Adjacent as a platform rewriting or designing genetic code for therapeutic applications, with overlapping target customers in gene therapy.
- Inscripta (now Telesis Bio): Platform for digital genome engineering, providing tools for writing and editing DNA at scale. Adjacent in providing infrastructure for optimizing genetic constructs for protein expression applications.
Broad incumbents
- Wave Life Sciences: Clinical-stage RNA medicines company developing stereopure oligonucleotides. Comparable as a nucleic-acid-based therapeutics platform; Dr. Paul Bolno (ExpressionEdits Chair) is Wave's CEO, providing a direct linkage.
- 4D Molecular Therapeutics: Clinical-stage gene therapy company with proprietary AAV vector discovery platform (Therapeutic Vector Evolution). Comparable as a gene therapy platform using engineered genetic constructs to improve therapeutic performance.
- BioNTech: Major mRNA therapeutics and gene therapy company with proprietary platforms for nucleic acid design and protein expression. Comparable as a large incumbent pursuing AI/ML-enhanced nucleic acid and protein therapeutics design.
Market position
Strengths1 record
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
ExpressionEdits social profiles
Digital presenceExpressionEdits compliance and trust
Trust signalCompliance2 records
ExpressionEdits financial estimates
Financial estimateRevenue estimate
Valuation estimate
ExpressionEdits leadership team
Management profileNumber of profiles
Profiles10 records
ExpressionEdits funding detail
Funding detailFunding overview
Funding rounds2 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ExpressionEdits M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ExpressionEdits
What does ExpressionEdits do?
ExpressionEdits develops an AI-driven computational platform called the Genetic Syntax Engine that predicts transgene performance and redesigns synthetic DNA sequences to enhance protein expression. Combined with its proprietary intronization technology—which integrates small introns (as small as 80 base pairs) into gene constructs—the company enables the production of therapeutic proteins previously considered infeasible and supports gene therapy optimization across therapeutic modalities.
Is ExpressionEdits a public or private company?
ExpressionEdits is a private company. It is classified as venture growth investor backed and is currently operating.
When was ExpressionEdits founded?
ExpressionEdits was founded in 2021. It employs 11 to 50 people.
Where is ExpressionEdits based?
ExpressionEdits is headquartered in Cambridge, United Kingdom, in the Europe region.
How does ExpressionEdits make money?
One revenue line is on record: strategic Partnerships and Collaborations.
Who are ExpressionEdits's main competitors?
Direct peers on record are Deep Genomics, Dyno Therapeutics, Generate Biomedicines, Cradle Bio and Asimov. Emerging players are Tessera Therapeutics and Inscripta (now Telesis Bio). Broad incumbents are Wave Life Sciences, 4D Molecular Therapeutics and BioNTech.
Does ExpressionEdits have an API?
No public API is recorded for ExpressionEdits.
What industry is ExpressionEdits in?
ExpressionEdits's product category is Computational Biology Platform. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 541714 and its SIC code is 2836.